Avellino Labs
Dr. Kim is a distinguished professor and Department Chairman in Ophthalmology at Yonsei University College of Medicine and an Ophthalmologist at Severance Hospital in Yonsei University Health System, Seoul, Korea. Dr. Kim is recognized globally for his expertise in granular corneal dystrophy, with over 140 authored peer-reviewed manuscripts on his research. He was the first to report Avellino Corneal Dystrophy (GCD2) as a contraindication to LASIK and subsequently that LASEK and PRK are also contraindicated. Dr. Kim performed molecular cell biology experiments about GCD2 and reported that the fibroblast from the cornea with GCD2 is suffering from oxidative stress. He is currently researching the pathophysiology of GCD2.
This person is not in the org chart
This person is not in any offices
Avellino Labs
Avellino Labs is a global leader in gene therapy and molecular diagnostics, and the pioneer in personalized medicine for eye care. Avellino Labs is pioneering CRISPR gene editing to manage and potentially cure inherited diseases. Avellino Labs continues to expand its diagnostics capabilities, building on the success of the world's first DNA test to confirm the presence of genetic indicators that are positively associated with corneal dystrophies, providing life-changing information for patient treatment decisions and follow up care. Avellino Labs is headquartered in Silicon Valley, California, with operations in Korea, Japan, China and the UK.